Altria: Dutiful
Altria raised 2026 adjusted EPS guidance to $5.66 to $5.74 and authorized more buybacks, while on! loses share as cigarette margins hold.
Altria raised 2026 adjusted EPS guidance to $5.66 to $5.74 and authorized more buybacks, while on! loses share as cigarette margins hold.
Why shouldn’t I buy $APP. It’s one of the greatest business models I’ve ever seen. https://t.co/qZ0lMlorvx
Is this bullish or bearish $C? https://t.co/mUh1Wdw99N
$HAWK now trading around $17.15, or -34% below its $26 IPO price. Initial lock-up expired last week, but I think it is unlikely many shares will come to market at these prices. $HAWK is also being added to the $IWM. $HAWK continues to have strong defense tech tailwinds, and they now have $500 mm+ of cash on hand. Valuation is now much more attractive and below the $18.86 price of their pre-IPO Series E financing.
@Maku_Capital It's a long list, some secular dynamics, some specific to $CASY, and competition, lots of it. This is not the right platform for me to lay out my entire short thesis....
$GME has 50%+ leases expiring in FY2026 and another 24% in FY2027 Maybe some risks in re-leasing at higher costs, but this is a huge advantage to walk away from unprofitable or underperforming stores fast https://t.co/mbsvLtgudI https://t.co/peHc0ImMzs
Anyone have thoughts on $B going into the North America spin post-Newmont settlement? Feels like it’s been a pretty consistent laggard vs. the gold peers despite the potential value unlock. Curious what I’m missing. https://t.co/0qYNp2oMpe
Agnico Eagle expects low-end 2026 guidance despite Barnat setbacks, while Hope Bay, Upper Beaver and Odyssey support production above 4…
Amazon reported Q3 2026 net sales up 12% year over year to $201.9 billion, narrowly below the $202.3 billion consensus estimate.
AAOI, Lumentum and Coherent 800G ramps, NVIDIA Rubin timing, and AMD, Intel and Arm server CPU demand frame an expert call on AI…
FTAI’s Aerospace Products margin rebounded to 31% as CFM56 module output rose, while Power deposits and contracted deliveries fund its 2027…
Anthropic’s revenue growth slowed from 147% in Q2 to 45% in Q3, raising questions about AI capital spending as Amazon holds capex flat.
American Tower could gain $1.13 to $3.54 in AFFO per share if Starlink accesses 80,000 U.S. cell sites and becomes a fourth major tenant.
Chevron’s Q3 revenue rose 35% to $65.2 billion and EBITDA 75% to $20.2 billion, while production trailed guidance and refining margins…
AstraZeneca reported $16.2 billion Q3 revenue, up 7%, as oncology grew 17% and Farxiga fell 25% after US generics.
Sanofi raised FY26 guidance after Q3 sales grew 14.3% at constant currency, led by 34.8% Dupixent growth; vaccines declined 6.6%.
SK hynix's U.S. ADR trades at a valuation discount despite AI-driven memory demand, with 50% of 2027–2028 capacity under long-term…
T · short AT&T’s stalled deleveraging and share repurchase case has prompted a bearish turn on the telecom stock.
Microsoft’s Azure grew 48% as AI monetization accelerated, but doubled CapEx, largely for CPUs and GPUs, reduced quarterly free cash flow…
Regeneron’s Q3 revenue rose 36% to $5.1 billion, driven by a 68% jump in Sanofi collaboration revenue, while operating income doubled to…
Bloom may have reopened imports of scandium-containing components from China to the United States, according to new trade data.
ExxonMobil’s Q3 revenue rose 33% to $113.2 billion as refining earned $9.1 billion, surpassing upstream; the company set 2027 buybacks at…
Amazon projects AWS growth above 40% through 2028 while funding a $220 billion capex plan with rising debt and an $80 billion equipment…
Markel spent $315 million repurchasing shares in Q3 as Thrive agreed to buy ADT for $7.6 billion and Hasbro cited rising adult toy demand.
Alphabet's Google Cloud operating income more than tripled to $11.1 billion, while EPS fell 26% on a $2.76 billion SpaceX paper loss.
Amazon reported $201.9 billion Q3 revenue and 39% AWS growth, while $220 billion in 2026 capex drove trailing free cash flow to a $42.4…
Amazon’s AWS revenue grew 39% to $46B as capex drove negative FCF; Lilly raised 2026 guidance to $91-92B on GLP-1 volume growth.
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.